相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。PARP1 and PARP2 stabilise replication forks at base excision repair intermediates through Fbh1-dependent Rad51 regulation
George E. Ronson et al.
NATURE COMMUNICATIONS (2018)
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors
Ann-Gerd Thorsell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Synthetic lethality and cancer
Nigel J. O'Neil et al.
NATURE REVIEWS GENETICS (2017)
PARP inhibitors: Synthetic lethality in the clinic
Christopher J. Lord et al.
SCIENCE (2017)
Neuroprotective effects of a novel poly (ADP-ribose) polymerase-1 inhibitor, JPI-289, in hypoxic rat cortical neurons
Youngchul Kim et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2017)
Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent
Bing Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
PARP inhibitors: the race is on
Jessica S. Brown et al.
BRITISH JOURNAL OF CANCER (2016)
An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy
Ying-Qing Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
Yves Pommier et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy
Gianluca Papeo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Pyrimidinone Nicotinamide Mimetics as Selective Tankyrase and Wnt Pathway Inhibitors Suitable for in Vivo Pharmacology
Jeffrey W. Johannes et al.
ACS MEDICINAL CHEMISTRY LETTERS (2015)
An NMR Method for the Quantitative Assessment of Intramolecular Hydrogen Bonding; Application to Physicochemical, Environmental, and Biochemical Properties
Michael H. Abraham et al.
JOURNAL OF ORGANIC CHEMISTRY (2014)
Rationale for Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy with Camptothecins or Temozolomide Based on PARP Trapping versus Catalytic Inhibition
Junko Murai et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Discovery of novel benzo[b][1,4]oxazin-3(4H)-ones as poly(ADP-ribose)polymerase inhibitors
Anthony R. Gangloff et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Parp-2 is required to maintain hematopoiesis following sublethal γ-irradiation in mice
Jordi Farres et al.
BLOOD (2013)
PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis
Marie-France Langelier et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2013)
PARP inhibitors: polypharmacology versus selective inhibition
Torun Ekblad et al.
FEBS JOURNAL (2013)
Identification of NVP-TNKS656: The Use of Structure-Efficiency Relationships To Generate a Highly Potent, Selective, and Orally Active Tankyrase Inhibitor
Michael D. Shultz et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Structural implications for selective targeting of PARPs
Jamin D. Steffen et al.
FRONTIERS IN ONCOLOGY (2013)
Genetic Interactions in Cancer Progression and Treatment
Alan Ashworth et al.
CELL (2011)
Evolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From Concept to Clinic
Dana V. Ferraris
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and-2 Mutant Tumors
Philip Jones et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Discovery of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the Treatment of Cancer
Thomas D. Penning et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1
Keith A. Menear et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
The influence of drug-like concepts on decision-making in medicinal chemistry
Paul D. Leeson et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Rational design of conformationally restricted quinazolinone inhibitors of poly(ADP-ribose)polymerase
Kouji Hattori et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
Discovery of potent and selective PARP-1 and PARP-2 inhibitors: SBDD analysis via a combination of X-ray structural study and homology modeling
J Ishida et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2006)
4-Phenyl-1,2,3,6-tetrahydropyridine, an excellent fragment to improve the potency of PARP-1 inhibitors
J Ishida et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2005)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Discovery of quinazolinone and quinoxaline derivatives as potent and selective poly(ADP-ribose) polymerase-1/2 inhibitors
A Iwashita et al.
FEBS LETTERS (2005)
Rational approaches to discovery of orally active and brain-penetrable quinazolinone inhibitors of poly(ADP-ribose)polymerase
K Hattori et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Design and synthesis of poly ADP-ribose polymerase-1 inhibitors.: 2.: Biological evaluation of aza-5[H]-phenanthridin-6-ones as potent, aqueous-soluble compounds for the treatment of ischemic injuries
D Ferraris et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse
JMN de Murcia et al.
EMBO JOURNAL (2003)
分享论文
